33 results about "Oral solutions" patented technology

The present application provides a detection method and quality control method for related substances in dextromethorphan oral solution, which comprises the following steps: dissolving dextromethorphan oral solution in a solvent to obtain a test solution; and performing high performance liquid chromatography detection on the test solution; the mobile phase used in the high performance liquid chromatography detection comprises mobile phase A and mobile phase B, the mobile phase A comprises a phosphate solution, the mobile phase B comprises acetonitrile, and the concentration of the phosphate solution is 0.1 mM-10 mM. The detection method has good linear relationship between dextromethorphan and related substances, good accuracy and sensitivity, strong specificity, high stability, good separation degree and good reproducibility, and is suitable for wide application.

The utility model discloses a kind of oral liquid bottle caps with quantitative drop hole, comprising: inner plug, insert in oral liquid bottle mouth;And outer cover, cover on oral liquid bottle mouth, and cover inner plug in it;The inner plug includes plug body;Dripping channel is provided in the middle part of the plug body, and dripping port is provided at the top of the plug body, and liquid inlet is provided at the bottom of the plug body, dripping port and dripping channel intercommunicate, and dripping channel and liquid inlet intercommunicate;Extension body structure is provided at the side of the plug body, airflow passage I that passes through up and down is provided in the extension body structure, airflow passage II that passes through up and down is provided in plug body, and airflow passage I is communicated with airflow passage II.The utility model does not need external suction tube or dropper, with quantitative dripping function, solve most oral solution in the course of taking cannot control medicine liquid drop speed and drop weight, cannot realize the problem of accurate quantitative dosing.

This utility model discloses a mixing tank for producing lactulose oral solution. Its structure includes a main body, an upper conveying cylinder, and a lower conveying cylinder. Raw materials are conveyed through the inlet to the upper conveying cylinders on both sides, causing the materials inside to move simultaneously towards the central connection port. The materials on both sides push against each other, resulting in the first stage of fusion. Then, under the influence of a lower spiral auger inside the lower conveying cylinder, the materials separate and move to both sides, thus performing a second stage of mixing. Subsequently, the materials are fed into the lower end of the main body through the discharge port. A third motor drives a rotating shaft, causing a stirring rod to agitate the materials again, resulting in further mixing. Then, at the lowest point, a fourth motor drives a rotating shaft, causing the stirring rod to rotate, thus mixing the materials again, resulting in higher mixing efficiency and better mixing effect.

This invention provides a sample pretreatment method and identification method for identifying ginseng polysaccharides in compound fluorouracil oral solution, belonging to the field of pharmaceutical detection and analysis technology. The sample pretreatment method of this invention includes: centrifuging the compound fluorouracil oral solution and taking the clear solution; adding silica gel to the clear solution, mixing, and removing the solvent to obtain a solid mixture; adding ethanol solution or anhydrous ethanol to the obtained solid mixture, heating and refluxing, discarding the ethanol solution, and obtaining the residue; adding water to the obtained residue, sequentially extracting and centrifuging, taking the supernatant obtained by centrifugation, removing the solvent from the supernatant, and then redissolving it with water; the identification method of this invention is thin-layer chromatography analysis, and the developing solvent includes the following components in parts by volume: 6.8-9.2 parts of n-propanol, 1.76-2.24 parts of water, 0.75-1.24 parts of ethyl acetate, and 0.75-1.24 parts of glacial acetic acid. The sample pretreatment method and identification method for identifying ginseng polysaccharides in compound fluorouracil oral solution of this invention have high specificity.

This invention provides an birepiperazole oral solution, wherein the solution comprises birepiperazole 0.4-0.6 mg / ml, disodium edetate 0.1-0.5 mg / ml, methylparaben 1.5-2.0 mg / ml, propylparaben 0.15-0.25 mg / ml, an acidic pH adjuster 2.5-3.5 mg / ml, a flavoring agent 0.8-1.2 mg / ml, propylene glycol 40-60 mg / ml, glycerin 120-180 mg / ml, and a sodium hydroxide solution to adjust the pH to 2.9-3.3. The drug exhibits high stability during preparation, storage, and clinical formulation.

Oral pharmaceutical solution comprising a pharmaceutically acceptable salt of lisdexamfetamine, and a pharmaceutically acceptable aqueous carrier comprising a buffer and a cosolvent selected from the group consisting of a glycol, a polyol, and a mixture thereof, wherein the pH of the solution is from 5.5 to 9.0. The oral pharmaceutical solution presents excellent physicochemical stability, even under alkaline conditions.

This invention discloses an oral liquid containing astaxanthin and its preparation method, which is prepared from raw materials comprising the following weight percentages: 0.5%~2% astaxanthin burst beads, 8%~12% collagen peptides, 0.1%~0.3% sodium hyaluronate, 0.01%~2% elastin peptides, 0.01%~0.05% spermidine, 0.005%~0.02% ergothioneine, and 0.001%~0.01% pyrroloquinoline quinone. The astaxanthin burst beads are prepared using astaxanthin oil as the core material and sodium alginate and chitosan as the wall material. This invention, by using astaxanthin burst beads with higher stability and bioavailability in the oral liquid, combined with other ingredients, can improve the user's skin moisture content and elasticity index, reduce wrinkle depth, reduce skin yellowing, and better exert the effects of the oral liquid.

The invention provides a method for detecting the contents of multiple index components of a coughing oral liquid, which comprises the following steps of: determining the contents of nine key pharmacodynamic index components, namely ephedrine hydrochloride, pseudoephedrine hydrochloride, apiose liquiritin, isoliquiritin, baicalin, huperzin A glycoside, wogonin, baicalein and wogonin; the detection method has the advantages of simplicity and convenience in operation, high stability, high pertinence and high practicability, can be used as a detection and evaluation method for production and internal quality components of the coughing oral liquid, and has a good market application prospect.

This invention provides a method for preparing a metformin compound hypoglycemic oral solution, relating to the pharmaceutical field, comprising: step S1, pretreatment of traditional Chinese medicine components; step S2, enzymatic hydrolysis of the first group of traditional Chinese medicine components; step S3, supercritical extraction; step S4, preparation of mixed traditional Chinese medicines; step S5, preparation of inclusion complex; step S6, compound formulation; and step S7, post-processing. This method synergistically combines extracts from seven traditional Chinese medicines—bitter melon, phellodendron bark, astragalus root, kudzu root, rehmannia root, ginseng, and privet fruit—with metformin hydrochloride to form a metformin compound hypoglycemic oral solution, balancing the synergy, safety, and stability of traditional Chinese and Western medicines, thereby improving hypoglycemic effects while reducing the incidence of gastrointestinal adverse reactions to metformin.

The present invention provides for an oral solution that includes atomoxetine, or pharmaceutically acceptable salt thereof, methods of manufacturing the oral solution, and methods of treating attention deficit hyperactivity disorder (ADHD) in a human subject that include orally administering the oral solution to a human subject in need thereof.

1. Name of the product in this design: Packaging Box (Iron Oral Liquid). 2. Intended use of this design: for packaging health food products. 3. The key design features of this product are the combination of pattern and color. 4. The image or photograph that best illustrates the design's key points: a 3D model. 5. The design for which protection is sought includes color.

1. The name of the design product: medicine packaging box (ibudilast oral solution). 2. The use of the design product: the design is used for the outer packaging of ibudilast oral solution. 3. The design points of the design product: the combination of shape, pattern and color. 4. The picture or photo that best indicates the design points: perspective view. 5. The design claimed contains color.

This invention provides a PND cyclodextrin inclusion complex, its preparation method, and its applications, relating to the field of pharmaceutical formulation technology. The method for preparing the PND cyclodextrin inclusion complex of this invention does not use organic solvents, is simple and easy to control, and has low cost. The technical solution of this invention greatly improves the solubility of PND in water, enhances the therapeutic effect of PND, and improves the stability of PND. This inclusion complex is suitable for preparing clinically required solid and liquid dosage forms, including infusions, injections, powder injections, oral solutions, novel nasal drops, nasal sprays, syrups, tablets, capsules, granules, and dispersible tablets. This inclusion complex can be used to prepare drugs for the prevention and treatment of influenza A virus infection.

Invention Title: A Method for Detecting Ethylene Glycol and Diethylene Glycol in Aripiprazole Oral Solution Abstract: This invention provides a method for detecting ethylene glycol and diethylene glycol in aripiprazole oral solution, applicable to the field of drug oral preparation detection technology, especially in the field of pharmaceutical quality control, requiring gas chromatography detection methods to monitor pharmaceutical excipients and byproducts. This analytical method overcomes the limitations of ethylene glycol and diethylene glycol, which lack ultraviolet absorption methods. The sample solution is injected into the injection port via a microsyringe, and instantly vaporized in a high-temperature vaporization chamber, increasing sensitivity and accuracy, and solving the problems of low detection efficiency and low precision. Separation and detection efficiency are improved by optimizing column temperature and other conditions. This invention uses high-performance gas chromatography (HPLC) with a 100% bonded cross-linked polyethylene glycol (PEG) capillary column, a flame ionization detector, nitrogen as the carrier gas, and an organic solvent as the diluent. It uses a conventional chromatographic column, an automated injection method, and reduces costs. Gradient temperature elution is employed for separation and detection. This invention relates to a method for the detection of ethylene glycol and diethylene glycol in aripiprazole oral solution. This method has good separation, high specificity, high precision, and good repeatability, and meets the requirements for methodological research on the determination of ethylene glycol and diethylene glycol in aripiprazole oral solution.

This utility model relates to the technical field of oral solution filtration equipment, specifically an oral solution filtration device, including a tank, a lid, a filter, a motor, a rotating shaft, and a cleaning rack. The lid is installed on the upper surface of the tank, and the filter is installed on the inner wall of the tank. The motor is fixedly connected to the upper surface of the lid, and the rotating shaft is fixedly connected to the surface of the motor drive shaft. The cleaning rack is fixedly connected to the surface of the rotating shaft and contacts the inner wall of the filter. A locking device is installed on the surface of the tank, including a mounting bracket, which is fixedly connected to the outer arc surface of the tank. This utility model, by setting a locking device, allows users to quickly disassemble the device, thereby reducing the time-consuming process of removing bolts and the resulting disruption to production time. This improves the convenience and timeliness of equipment maintenance and effectively ensures production continuity.

This invention discloses a method for determining the content of magnesium sulfate sodium potassium oral concentrate. The method includes taking a sample of the magnesium sulfate sodium potassium oral concentrate, diluting it with an ammonium chloride solution containing approximately 0.18 mmol / L ammonium ions as a solvent, performing ion chromatography with specific chromatographic parameters, and calculating the content of magnesium sulfate, sodium sulfate, and potassium sulfate in the solution using the external standard method. This invention is simple to operate, time-saving, labor-saving, easy to master, highly specific, accurate, and precise, providing accurate results. It can be used for the determination of the content of magnesium sulfate sodium potassium oral concentrate.

This utility model discloses a gas-fired steam generator specifically for sterilizing choline oral solution, belonging to the technical field of steam generators. Its key technical features include a gas-fired steam generator body, a display screen, two instruments, several pipes, and a heat dissipation mesh. Support plates are fixedly connected to the top and bottom of the front side of the gas-fired steam generator body. A brushing mechanism is provided on the front side of the heat dissipation mesh, and a suction mechanism is provided on the right side of the brushing mechanism. The brushing mechanism includes a fixed plate, several brush bristles, a rotating plate, and a variable frequency motor. This invention solves the problem that in some existing traditional gas-fired steam generators for sterilizing choline oral solution, the heat dissipation mesh becomes dusty and difficult to clean after prolonged use. When workers use a hand brush to remove dust, the dust easily disperses into the gas-fired steam generator, making cleaning even more difficult and affecting the normal heat dissipation of the internal equipment during operation.

The application discloses a compound calcium gluconate oral solution and a preparation process thereof. The compound calcium gluconate oral solution comprises the following raw materials in mass fractions: 40-60 parts of calcium gluconate, 40-60 parts of calcium lactate, 5-5.5 parts of a stabilizer, 140-160 parts of sucrose, 30-40 parts of glucose, 0.1-0.3 parts of essence and the balance of purified water. The pH value of the obtained compound calcium gluconate oral solution is 4.0-5.0, and the stabilizer comprises lactic acid and modified inulin in a mass ratio of 1: (0-0.08). The calcium lactate has a high solubility in water and can also serve as a solubilizer of the calcium gluconate, thereby improving the solubility of the calcium gluconate in water. The lactic acid in the stabilizer can dissociate into lactate ions, further improving the solubility of calcium ions in the system. The modified inulin has a good effect of preventing crystallization, thereby reducing the occurrence of crystallization precipitation.

This application relates to compositions and methods for use in vancomycin oral solutions. The invention relates to stable vancomycin hydrochloride powder for use in oral liquid formulations. Methods for using vancomycin oral liquid formulations to treat certain diseases (e.g., Clostridium difficile pseudomembranous colitis and staphylococcal enterocolitis), as well as related kits and products, are also provided herein.

This application discloses a method for determining the content of zinc gluconate oral solution, belonging to the field of pharmaceutical quality testing technology. The method uses disodium ethylenediaminetetraacetate titration, adding ammonium fluoride and Eriochrome Black T indicator to an ammonium chloride buffer system. Titration continues until the solution changes from purple-red to blue-green and remains unchanged for 30 seconds. The zinc gluconate content is calculated based on the titration volume. This method eliminates interference from sample color and excipients, accurately determines the endpoint, and has demonstrated good specificity, precision, accuracy, and stability through experiments. It is suitable for determining the content of near-colorless samples, samples with deepened color, samples tested at high temperatures, and commercially available samples from different manufacturers. The method is simple to operate, low in cost, and can meet the routine quality control requirements of zinc gluconate oral solution.

1. Name of the product in this design: Packaging Box (Concentrated Type of Pediatric Cough and Asthma Oral Liquid). 2. Purpose of this design: For packaging concentrated pediatric cough and asthma oral liquid produced by Beijing Yadong Biopharmaceutical Co., Ltd. 3. The key design elements of this product are the combination of shape, pattern, and color. 4. The image or photograph that best illustrates the design's key points: a 3D model. 5. The design for which protection is sought includes color.

The application discloses a detection method of a degradation impurity 3-methyl-1-propanol in a fudosteine oral solution, relates to the technical field of drug degradation product analysis, and solves the technical problem that a quantitative analysis method for the degradation product 3-methyl-1-propanol in the fudosteine oral solution is lacked in the prior art; the detection method is high-performance liquid chromatography, a chromatographic column with octadecylsilane bonded silica gel as a filling agent is used, an ultraviolet detector is used, an organic solvent aqueous solution is used as a mobile phase, and isocratic elution is used; wherein the organic solvent in the mobile phase is methanol or acetonitrile; the method is high in specificity, high in sensitivity, good in accuracy, can effectively determine the content of the 3-methyl-1-propanol in the fudosteine oral solution, and thus guarantees controllable quality of the fudosteine oral solution.

This invention belongs to the field of pharmaceutical technology, specifically a ferric protein succinate oral solution and its preparation method. The ferric protein succinate oral solution, by weight percentage of the total prescription volume, comprises: 5.33% ferric protein succinate raw material, 5-20% sweetener, 5-20% solvent, 0.5-2% preservative, 0.1-0.5% sweetener, 0.5-2% flavoring agent, and purified water to a final volume of 15 ml; wherein the preservative is benzoic acid or sodium benzoate. This invention, through screening the prescription and process parameters, can increase the dissolution rate of the ferric protein succinate raw material, reduce the time ferric protein succinate spends at high temperatures, reduce the adverse effects of high temperatures on ferric protein succinate, and simultaneously reduce the solution viscosity, making it easier to fill and more suitable for commercial production. The dispensing process is efficient and simple to operate.

The application provides an oral solution for treating stress urinary incontinence, a preparation method and application, and is mainly prepared from the following raw materials in mass parts: 7-20 parts of raspberry, 8-21 parts of cherokee rose, 8-15 parts of dried river snail, 7-20 parts of sago palm fruit, 3-15 parts of radix codonopsis, 6-12 parts of poria cocos, 11-17 parts of white atractylodes, 10-16 parts of licorice, 8-14 parts of angelica, 8-20 parts of ligustrum lucidum ait, 7-11 parts of medlar, 8-16 parts of dodder seed, 7-15 parts of cornus officinalis, 9-18 parts of black amur vine fruit, 6-12 parts of schisandra chinensis, 4-10 parts of rhizoma cimicifugae, 5-11 parts of immature fruit of citrus aurantium, 1-6 parts of gelatin mixture, 8-48 parts of distilled water, 27-38 parts of ethanol, 80-480 parts of liquid paraffin, 1.6-9.6 parts of Span80, 0.8-4.8 parts of glutaraldehyde, 8-48 parts of isopropyl alcohol and 0.6-3.6 parts of Fe3O4. The oral solution is convenient to absorb, has less side effects and good treatment effect.

This invention belongs to the field of pharmaceutical quality testing technology, specifically relating to a method for detecting isomer content in briracetam oral solution. The detection method of this invention involves preparing a solution and employing high-performance liquid chromatography (HPLC) using chromatographic columns 1 and 2 connected in series and a valve-switched flow path. The HPLC chromatographic conditions include: column 1, column 2; mobile phase A: organic acid solution; mobile phase B: acetonitrile; elution mode: gradient elution; valve switching settings: column 1 is connected to the main flow path, and column 2 and the two separate channels are connected to parallel channels. The column 2 channel is used at 6 and 20 min, and the two separate channels are used at 9 and 50 min. The method for detecting isomer content in briracetam oral solution provided by this invention has high sensitivity, good specificity, system applicability, and solution stability, providing an effective prescription analysis method for drug development.

The present disclosure relates to the technical field of capping machines, and one embodiment of the present disclosure provides a rapid capping machine for producing oral solutions, which comprises a rack, a conveying mechanism arranged on the rack, a storage cylinder, two limiting frames, a centering frame, a pressing mechanism and a limiting mechanism, the storage cylinder is fixedly connected in the rack and located above the conveying mechanism, the two limiting frames are arranged at the bottom end of the storage cylinder through a swing mechanism, the indirect falling of the bottle cap is controlled to each bottle mouth, the centering frame is arranged in the rack through a moving mechanism, the moving mechanism is used for driving the centering frame to center the bottle cap on the bottle mouth, and the pressing mechanism is arranged in the rack. Through the above technical scheme, the technical problem that the bottle cap is prone to tilting on the bottle mouth after the bottle cap falls on the bottle mouth through free fall in the prior art, which is prone to causing damage to the bottle cap when the pressing frame compacts the bottle cap, and further affecting the capping effect is solved.